Extended Rituximab Plus R-CHOP Best in Elderly, Poor-Prognosis DLBCL

Extended Rituximab Plus R-CHOP Best in Elderly, Poor-Prognosis DLBCL

"Elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) may derive the most benefit from treatment with extended rituximab plus 6 cycles of R-CHOP on a 14-day schedule, according to the results of the SMARTE-R study published in the Journal of Clinical Oncology."

cancernetwork.com/news/exte...

Encouraging news with a 3-year overall survival of 84% for all patients

Neil

Photo: Some red flowers in the rain on a member of the mint family - Lamiaceae. This plant had my researcher Jay struggling for quite a while before he finally identified the plant. If I'd just crushed one of the leaves, the strong mint smell would have given a very big clue!

1 Reply

oldestnewest
  • This must be a final update, this study was presented at ASH in 2011

    ash.confex.com/ash/2011/web...

    Might be interesting to see the results in a head to head RCHOP-21/RCHOP-14 + Rituxan dose density... previous trials didn't find much difference between the two... as I recall.

    Perhaps the way the rituxan is dosed makes the difference... perhaps Gazyva (obinutuzimab) would be a better trial next time?

    ~chris

You may also like...